Robert A. Bradway is Amgen’s chairman and chief executive officer. He became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.
Prior to joining Amgen, Bradway was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.
Bradway is a member of the board of directors of The Boeing Company, chairing its Governance and Public Policy Committee and serving on its Compensation Committee. He also serves as a board member of the W. M. Keck Foundation and the Pharmaceutical Research and Manufacturers of America (PhRMA). In addition, Bradway serves on the board of trustees of the University of Southern California, he is an Emeritus Director of the CEO Roundtable on Cancer, and he is a member of the American Heart Association CEO Roundtable, which is helping the Association meet its goal of improving the cardiovascular health of all Americans.
FIRM PROFILE
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and we are also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas, oncology, inflammation, general medicine and rare disease, delivering innovative medicines to help people live longer, fuller, happier lives.
Investing in Science and Innovation
We pursue new ways to do science using tools like AI, generative biology and human data to discover what is not yet known and develop new precision medicines to fight the world’s toughest diseases.
Making Medicines Safely and Reliably
Many of Amgen’s medicines are made through a highly complex process involving living cells. Our commitment is to deliver for “every patient, every time”, and we have a long-running reputation for the reliability of our supply chain.
Operating Responsibly
Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines. We also help build a better world by focusing on environmental, social and governance issues that matter most to our business and our stakeholders.
